FDA Fast Tracks New Pleural Mesothelioma Drug
The U.S. Food & Drug Administration (FDA) has decided to fast track SELLAS™ Life Sciences’ new drug Galinpepimut-S to treat pleural mesothelioma
The U.S. Food & Drug Administration (FDA) has decided to fast track SELLAS™ Life Sciences’ new drug Galinpepimut-S to treat pleural mesothelioma